The aim of this study is to be able to make better predictions about the further development of the disease and about the effects of the disease on the metabolism, the cardiovascular system and the quality of life.
Aim of the study
The aim of this study is to be able to make better predictions about the further development of a pheochromocytoma or paraganglioma and about the effects of the disease on the metabolism, the heart and the quality of life.
Who can take part?
Anyone who suffers from a pheochromocytoma / paraganglioma, has been treated for one in the past or has a high probability of developing the disease for family/genetic reasons can take part.
Procedure
The first step is a medical assessment to determine whether you are suitable to participate in this study. You will be asked about your health and your medical history. Next, the hormones and hormone degradation products produced by pheochromocytomas/paragangliomas are measured in the blood and urine. Depending on these results, further examinations, e.g. imaging examinations, may then be necessary. In addition, examinations are carried out to determine the influence of hormones on the cardiovascular system (blood pressure measurement, examination of the pumping capacity and rhythm of the heart, ultrasound examination of the vessels). The examinations mentioned do not differ from those that are carried out on patients with your disease outside of this study. The main difference is that if you participate in the study, the data collected will be used for scientific purposes. If you have agreed to participate in a biospecimen study, additional blood samples will be taken for scientific purposes only.
Compensation
None
Original study name
Multicenter pheochromocytoma and paraganglioma evaluation for follow-up screening, genetic subtyping, therapy and outcome
BASEC number
2017-00963
Financial support from
University Hospital Zurich